Helius Medical Technologies, Inc. (HSDT)

NASDAQ: HSDT · IEX Real-Time Price · USD
1.25
-0.31 (-19.87%)
At close: Jun 24, 2022 4:00 PM
1.57
+0.32 (25.60%)
After-hours: Jun 24, 2022 4:11 PM EDT
-19.87%
Market Cap 4.87M
Revenue (ttm) 628,000
Net Income (ttm) -19.12M
Shares Out 3.90M
EPS (ttm) -6.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,616
Open 1.63
Previous Close 1.56
Day's Range 1.25 - 1.63
52-Week Range 1.06 - 17.10
Beta 0.86
Analysts Buy
Price Target 25.50 (+1,940.0%)
Earnings Date Aug 11, 2022

About HSDT

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The compan... [Read more...]

Industry Health Care Equipment & Supplies
CEO Philippe Deschamps
Employees 19
Stock Exchange NASDAQ
Ticker Symbol HSDT
Full Company Profile

Financial Performance

In 2021, HSDT's revenue was $522,000, a decrease of -21.03% compared to the previous year's $661,000. Losses were -$18.13 million, 28.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for HSDT stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 1,940.00% from the latest price.

Price Target
$25.5
(1,940.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Helius Medical Technologies, Inc. (HSDT) Upgraded to Buy: Here's Why

Helius Medical Technologies, Inc. (HSDT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annua...

-- Study finds significant improvement in gait deficit in multiple sclerosis patients using translingual neurostimulation (“PoNS Therapy®”) combined with a therapeutic exercise program -- -- Poster was ...

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

New program seeks to expand access to patients suffering from multiple sclerosis (MS) New program seeks to expand access to patients suffering from multiple sclerosis (MS)

Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Confer...

NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an...

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

NEWTOWN, Pa., May 24, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that, ...

Helius Medical Technologies, Inc. Announces Participation of Dr. Deborah Backus and Shepherd Center in its Therapeuti...

-- Second Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects' adherence to PoNS® therapy for gait improvement...

Helius Medical Technologies, Inc. Reports First Quarter 2022 Financial Results and Provides Update on U.S. Commercial...

-- Company to host call at 9:00am today with CEO, CFO, CMO and VP Sales & Marketing -- NEWTOWN, Pa., May 12, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Co...

Helius Medical Technologies, Inc. to Release First Quarter 2022 Financial Results on May 12, 2022

NEWTOWN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announ...

Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®

-- First patients have purchased PoNS devices to initiate PoNS Therapy -- -- Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch -- NEWTOWN, Pa., April 27, 20...

Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability

-- Breakthrough technology for MS patients helps patients with gait deficit

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

NEWTOWN, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financi...

Helius Medical Technologies, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTOWN, Pa., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT ) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that,...

Helius Medical Technologies, Inc. Provides Corporate Update

-- Fourth Quarter 2021 Revenue Projected to Range from $250,000 to $260,000 -- -- Unaudited Year End Cash Balance of $11 million --

Helius Medical Technologies, Inc. Partners with the Medical University of South Carolina in Pilot Trial on Stroke

-- PoNS ® to be used in study of cranial-nerve non-invasive neuromodulation and dynamic gait balance in stroke patients -- -- Collaboration will inform Helius's registrational program in stroke --

Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®

Patent Readies Company for Next Generation of PoNS Therapy Patent Readies Company for Next Generation of PoNS Therapy

Helius Medical Technologies, Inc.'s Dr. Antonella Favit-Van Pelt to Present at 4th International Brain Stimulation Co...

Dr. Favit-Van Pelt will present research that led to the FDA authorization of translingual nerve stimulation for gait disturbance in multiple sclerosis Dr. Favit-Van Pelt will present research that led ...

Helius Medical Technologies, Inc. to Participate in 1x1 Meetings at 12th Annual Craig-Hallum Alpha Select Conference ...

NEWTOWN, Pa., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (Helius), a neurotech company focused on neurological wellness, today announced that Dane C. Andreeff, Pr...

Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Inc...

NEWTOWN, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the cl...

Helius Medical Technologies, Inc. Reports Third Quarter 2021 Financial Results

NEWTOWN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported financia...

Helius Medical Technologies, Inc. (HSDT) Reports Q3 Loss, Tops Revenue Estimates

Helius Medical Technologies, Inc. (HSDT) delivered earnings and revenue surprises of -14.86% and 37.98%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead ...

Helius Medical Technologies, Inc. Announces Pricing of $9.6 Million Underwritten Public Offering of Common Stock

NEWTOWN, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the pr...

Helius Medical Technologies, Inc. Announces Proposed Underwritten Public Offering of Common Stock

NEWTOWN, Pa., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that i...

Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Tri...

-- Multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects' adherence to PoNS ® therapy for gait improvement in Multiple Sclerosis -- -- Program to ...

Helius Medical Technologies, Inc. Receives PoNS® Market Authorization in Australia

NEWTOWN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced it received...

Helius Medical Technologies, Inc. (HSDT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Helius Medical Technologies, Inc. (HSDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.